Terms: = Colorectal cancer AND HOXA13, P31271, 3209, ENSG00000106031, HOX1J, HOX1 AND Treatment
4 results:
1. hoxa13 serves as a biomarker to predict neoadjuvant therapy efficacy in advanced colorectal cancer patients.
Liu S; Zhang R; Yang Z; Wang Y; Guo X; Zhao Y; Lin H; Xiang Y; Ding C; Dong Z; Xu C
Acta Biochim Biophys Sin (Shanghai); 2022 Dec; 55(2):304-313. PubMed ID: 36514224
[TBL] [Abstract] [Full Text] [Related]
2. IGF1-mediated hoxa13 overexpression promotes colorectal cancer metastasis through upregulating ACLY and IGF1R.
Qiao C; Huang W; Chen J; Feng W; Zhang T; Wang Y; Liu D; Ji X; Xie M; Sun M; Fan D; Wu K; Xia L
Cell Death Dis; 2021 Jun; 12(6):564. PubMed ID: 34075028
[TBL] [Abstract] [Full Text] [Related]
3. Utility of serum anti-cetuximab immunoglobulin E levels to identify patients at a high risk of severe hypersensitivity reaction to cetuximab.
Dupont B; Mariotte D; Dugué AE; Clarisse B; Grellard JM; Babin E; Chauffert B; Dakpé S; Moldovan C; Bouhier-Leporrier K; Reimund JM; Di Fiore F; Zanetta S; Mailliez A; Do P; Peytier A; Galais MP; Florescu C; Schott R; Le Mauff B; Gervais R
Br J Clin Pharmacol; 2017 Mar; 83(3):623-631. PubMed ID: 27662818
[TBL] [Abstract] [Full Text] [Related]
4. Systematic review of prognostic factors related to overall survival in patients with stage IV colorectal cancer and unresectable metastases.
Stillwell AP; Ho YH; Veitch C
World J Surg; 2011 Mar; 35(3):684-92. PubMed ID: 21181473
[TBL] [Abstract] [Full Text] [Related]
